Molecular Pathology in Oral Lesions

On this page
  1. Direct answer
  2. What you must remember
  3. Turning one ambiguous slide into a molecular answer
  4. Where students slip
  5. Frequently asked questions
  6. Related topics

Direct answer

The microscope now shares the diagnostic bench with the thermal cycler: immunohistochemistry reads proteins, fluorescent in-situ hybridisation and PCR detect the gene rearrangements and fusions that define tumours, and next-generation sequencing panels read dozens of genes from a single block of routine paraffin tissue. In the oral pathology of examinations, the payload is a map of named alterations: PTCH1 lost in the odontogenic keratocyst and germline-mutated in Gorlin syndrome; GNAS activating fibrous dysplasia and SH3BP2 mutated in cherubism; the fusion pairs CRTC1-MAML2, ETV6-NTRK3, MYB-NFIB and PLAG1/HMGA2 partitioning salivary tumours; immunoglobulin and T-cell receptor clonality separating neoplastic from reactive lymphoid infiltrates; and p16 immunohistochemistry standing in, with confirmation, for transcriptionally active HPV in oropharyngeal carcinoma.

What you must remember

  • Technique-to-question mapping: immunohistochemistry (protein expression), FISH (amplifications and structural rearrangements via break-apart probes — the ETV6 assay is the example examiners quote), RT-PCR (fusion transcripts), NGS panels (many genes, small input), IgH/TCR clonality PCR (lymphoid clonality), and methylation profiling (emerging classifiers).
  • Gorlin syndrome and PTCH1: germline mutation of the tumour suppressor at 9q22.3 in the Hedgehog pathway; multiple odontogenic keratocysts from the early teens, basal cell carcinomas, falx calcification, bifid ribs, palmoplantar pits, medulloblastoma risk — the jaw cysts are frequently the first sign, so the diagnosis is dental.
  • Fibro-osseous genetics: GNAS activating mutations (mosaic, post-zygotic) in fibrous dysplasia; SH3BP2 mutation in cherubism — a reliable two-mark matching question.
  • Salivary fusion map: CRTC1/3-MAML2 for mucoepidermoid carcinoma, ETV6-NTRK3 for secretory carcinoma (with TRK-inhibitor therapy implications), MYB/MYBL1-NFIB for adenoid cystic carcinoma, and PLAG1 or HMGA2 rearrangements in pleomorphic adenoma — with HMGA2 amplification accompanying progression to carcinoma ex pleomorphic adenoma.
  • Clonality: PCR of immunoglobulin heavy chain and T-cell receptor rearrangements distinguishes monoclonal neoplasia from polyclonal reactive infiltrates — the molecular question behind every "atypical lymphoid aggregate".
  • HPV surrogate: p16 immunohistochemistry overexpression in oropharyngeal carcinoma; positive staining is confirmed by E6/E7 in-situ hybridisation or PCR — surrogate and confirmatory test are separate marks.
  • Odontogenic epithelium and beyond: BRAF V600E in ameloblastoma links to MAPK-targeted therapy; adamantinomatous craniopharyngioma shares CTNNB1 — developmental kinship worth a viva sentence.
  • Pre-analytical limit: decalcified bone damages DNA and epitopes alike — formic acid or EDTA decalcification preserves testable material.

Turning one ambiguous slide into a molecular answer

A 45-year-old has a slowly growing palatal mass whose biopsy shows a basaloid tumour in cribriform nests — adenoid cystic carcinoma and its mimics (basal cell adenocarcinoma, secretory carcinoma among them) sit on the differential. Morphology alone hesitates, so the panel is reasoned, not sprayed: S-100 and mammaglobin stain diffusely, CD117 is weak, and the ETV6 break-apart FISH probe shows separation — the diagnosis is secretory carcinoma, not adenoid cystic, a distinction with immediate consequence: ETV6-NTRK3 fusions make metastatic disease uniquely treatable with TRK inhibitors, and the prognosis differs. In the same laboratory that week, a 16-year-old with a second keratocyst at the mandibular angle proceeds to germline PTCH1 testing, and a positive result converts her care from cyst surgery to syndrome surveillance — annual panoramic radiographs, skin surveillance, and family counselling. The unifying teaching is that the molecular result changes management only when the question is chosen to match the decision: fusion testing for the palatal mass, germline testing for the cysts.

Where students slip

The technique-confusion pair: attributing chromosomal translocations to immunohistochemistry (protein-level, not DNA-level) or asking FISH to quantify expression — matching the platform to the question is exactly what the viva examines. The surrogate trap: calling a p16-positive oral cavity carcinoma "HPV-driven" — p16 is a functional surrogate validated in the oropharynx, and oral cavity tumours require confirmatory E6/E7 testing before any biological claim. And the integration error: offering molecular tests as the starting point rather than the finish of morphology; panels resolve selected differential questions, they do not replace the haematoxylin-eosin section that frames them — the phrase "molecular complements, never replaces, morphology" is the mark-winning sentence.

Frequently asked questions

Which gene is mutated in Gorlin syndrome?

PTCH1, a tumour suppressor on chromosome 9q22.3 of the Hedgehog pathway — germline mutations underlie the multiple keratocysts, basal cell carcinomas and skeletal signs.

Which technique detects the ETV6-NTRK3 fusion?

Break-apart FISH on tissue sections, or RT-PCR for the fusion transcript — both applicable to routine paraffin material.

What does clonality testing by PCR establish?

Monoclonal immunoglobulin or T-cell receptor gene rearrangement, separating a neoplastic lymphoid proliferation from a polyclonal reactive infiltrate.

Why is p16 called a surrogate marker?

Because HPV E7 disables retinoblastoma protein, the cell compensates with p16 overexpression; the stain marks the consequence, and confirmatory E6/E7 testing establishes HPV itself.

What mutations define fibrous dysplasia and cherubism?

GNAS activating mutations in fibrous dysplasia; SH3BP2 mutations in cherubism — both examined as fixed pairings.

Which genes are rearranged in pleomorphic adenoma?

PLAG1 and HMGA2, with HMGA2 amplification accompanying progression toward carcinoma ex pleomorphic adenoma.

Practise this in the PrepElephant app

Question banks, previous-year questions, mock tests and revision tools — for Molecular Pathology in Oral Lesions and NEET-MDS Oral Pathology. Free to start.

Get the free app WhatsApp